StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) income statement

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)

Close on Nov 18, 2026Market cap $1.67BP/E –Yield –

Braveheart Bio, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
21.57
Debt to equity
–
Debt to assets
–
Cash to current liabilities
727.5%

Valuation

P/E ratio
–
Price to sales
–
Price to book
3.35
Dividend yield
–

See a number that looks wrong?